NSCLC EGFR Exon 20 — Master Protocol

Healthy tissue is largely spared because (i) gcMAF acts through endogenous Vitamin D-binding protein that is naturally present in human plasma and is a normal physiological regulator of macrophage tone, (ii) the OA-GcMAF/NO triad preferentially damages cells with weak NO-detoxification (a metabolic hallmark of malignant cells), (iii) the intrinsic-apoptosis route via caspase-9/cytochrome-C is engaged primarily in metabolically stressed malignant cells, and (iv) healthy cells do not secrete nagalase, so gcMAF homeostasis is preserved. However, two healthy-cell caveats exist: (a) gcMAF also activates microglia (B7-2, Iba1) and can protect neurons from chemotherapy-induced apoptosis (Branca 2015; Morucci 2015), which is beneficial against oxaliplatin neuropathy but could theoretically blunt c...

Direct evidence for gcMAF in NSCLC — and especially EGFR exon 20 NSCLC cancer stem cells (CSCs) or their metabolism — is essentially absent in the peer-reviewed PubMed literature. The closest available evidence is: (1) Inui et al., Anticancer Res 2016 (PMID 27354652) — a single case report of a 77-year-old male with stage 3B NSCLC treated with second-generation serum gcMAF plus oral colostrum MAF combined with sonodynamic therapy, tumor-treating fields and ozone therapy, demonstrating feasibility without adverse effects (no EGFR-genotype, no CSC-marker, no metabolic-readout data). (2) Hamilton et al., Oncoimmunology 2016 (PMID 27141354) — using SCLC (not NSCLC) CTC lines, showed that lung-cancer CTCs secrete VDBP that gives rise to gcMAF and simultaneously reprogram macrophages into TAMs, ...

Policosanol and octacosanol show preferential antitumor activity against multiple cancer cell lines (A549 lung adenocarcinoma, SNU-16 gastric, Ehrlich ascites, MDA-MB-231 triple-negative breast, HT-29 colon) while being non-cytotoxic to normal MCF-10a breast epithelial cells and NIH/3T3 fibroblasts (PMID 42064439). In endothelial and macrophage models, octacosanol protects healthy endothelium from LPS-induced inflammation and junction loss while suppressing inflammatory signalling. The proposed cancer selectivity likely stems from (i) cancer-cell reliance on dysregulated cholesterol/mevalonate flux for membrane biogenesis, (ii) tumour-specific reliance on VEGF/NF-κB-driven angiogenesis and inflammation that octacosanol damps, and (iii) potentially higher uptake by rapidly dividing cells of...

Direct evidence for Nano-Ojas/Metadichol in NSCLC EGFR exon 20 cancer stem cells is essentially ABSENT. PubMed search reveals (1) one in vitro + in vivo NSCLC study of free octacosanol (PMID 42193927, A549 lung adenocarcinoma — A549 carries a KRAS mutation, NOT an EGFR exon 20 insertion) demonstrating anti-metastatic and anti-angiogenic activity via MMP2/MMP9, JAK3/STAT3, PI3K/AKT, VEGF/CD31 suppression; (2) one gastric cancer xenograft of policosanol (PMID 36277362); (3) no Metadichol®-branded oncology study in PubMed; (4) no published study specifically on EGFR exon 20 insertion-mutant NSCLC; (5) no published study on NSCLC cancer stem cells (CD133+, ALDH+, side-population) with policosanol, octacosanol, triacontanol or Metadichol. The mechanistic rationale for CSC application rests on i...

Apigenin shows marked selective cytotoxicity towards NSCLC cells (A549, H1299, H1975, NCI-H460, EBC-1) and CD133+ lung cancer stem cells while sparing normal bronchial epithelium (BEAS-2B) and non-malignant endothelial cells in head-to-head comparisons (e.g. Euphorbia rigida extract study). It is described as a 'naturally occurring, non-toxic flavonoid' with antioxidant, anti-apoptotic (in normal cells) and anti-inflammatory properties in healthy tissue, while switching to a pro-apoptotic, pro-oxidant, pro-ferroptotic phenotype in cancer cells. Its toxicity profile in xenografts (no obvious organ toxicity by H&E staining) supports a favourable therapeutic window.

direct_evidence: Li et al., Nutr Cancer 2021 (PMID 32757802): Apigenin eliminates CD133+ lung cancer stem cells isolated from NSCLC A549, H1299 and cisplatin-resistant A549R cells; apigenin represses CD133+ fraction and potentiates cisplatin's antitumor effect; the CSC-depletion mechanism is p53-dependent (blocked by Pifithrin-α and p53 siRNA). This is the most direct published NSCLC CSC evidence for apigenin.; indirect_evidence: EXCLI J 2025 (PMID 40630468): Apigenin listed among small-molecule disruptors of YAP/TAZ (Hippo pathway), a core CSC-maintenance axis in EGFR-TKI-resistant lung cancer.; Eur J Med Chem 2025 (PMID 40752339): Review notes apigenin/quercetin suppress MET-mediated invasion and reverse CSC maintenance in NSCLC, supporting CSC-targeting potential.; Curr Pharm Des 2021 (...

cancer_cells: Halofuginone consistently suppresses proliferation, induces apoptosis/autophagy, and reverses drug resistance across multiple cancer cell lines and patient-derived xenografts. In NSCLC: HF reverses EGFR-TKI resistance (HCC827, H1975) by SP1 degradation → PSAT1 downregulation → Ser/Gly starvation; HF eradicates Nrf2-activated lung adenocarcinoma; HF sensitises patient-derived lung cancer organoids to cisplatin via PI3K/AKT + MAPK dual inhibition; HF induces ROS-dependent apoptosis + autophagy + G0/G1 arrest. In AML: HF inhibits leukaemic infiltration and extends OS in MLL-AF9-transduced AML mice. In chordoma: HF induced significant tumour-growth inhibition in PDX. In ovarian cancer: HF + chemotherapy enhances chemosensitivity via COL1A1 disruption and M2→M1 macrophage polarisa...

direct_evidence: DIRECT NSCLC evidence (4 papers): (1) PMID 40354707 — Phytomedicine 2025 — HF reverses EGFR-TKI resistance in HCC827 (EGFR exon 19 del) and H1975 (L858R/T790M) via SP1 degradation → PSAT1 downregulation → Ser/Gly synthesis defects. (2) PMID 39710292 — Eur J Pharmacol 2024 — HF inhibits HCC827 and H1975 proliferation, induces ROS-dependent autophagy + apoptosis + G0/G1 arrest; in-vivo HCC827 xenograft growth suppression. (3) PMID 34901018 — Front Cell Dev Biol 2021 — HF sensitises patient-derived lung cancer organoids to cisplatin via PI3K/AKT + MAPK dual inhibition. (4) PMID 35618180 — Free Radic Biol Med 2022 — HF micelle (HFm) eradicates Nrf2-activated lung adenocarcinoma without systemic toxicity.; egfr_exon_20_specific_evidence: ZERO PubMed-indexed studies directly str...

cancer_cell_effect: Verteporfin preferentially kills cancer cells through YAP/TAZ-TEAD disruption + autophagy/mitophagy blockade + ER stress induction. In NSCLC: (i) Hsu 2016 (PMID 27409162) — VP + erlotinib synergistically reduces migration, invasion, and TUMOR SPHERE FORMATION (CSC readout) in H1975 (L858R+T790M EGFR-TKI-resistant) cells; YAP overexpression drives erlotinib resistance in HCC827 (EGFR exon 19 deletion) cells. (ii) Jeong 2022 (PMID 35785700) — VP reduces viability of PC9 (EGFR exon 19 del) and GEFITINIB-RESISTANT PC9 cells via ANO1 + EGFR-STAT3 downregulation, induces caspase-3/PARP-1 cleavage apoptosis, IC50 ~300 nM. (iii) Park 2021 (PMID 33486901) — VP effectively kills EGFR-TKI-resistant lung adenocarcinoma cells (PC9/GR, HCC827/GR) by lowering p62 (oncogenic), YAP, and...

direct_evidence: Hsu 2016, PMID 27409162, Oncotarget: VP increases sensitivity of H1975 (L858R+T790M, EGFR-TKI-resistant) cells to erlotinib; VP + erlotinib synergistically reduces MIGRATION, INVASION, and TUMOR SPHERE FORMATION (the gold-standard CSC functional assay) in H1975 cells. YAP overexpression drives erlotinib resistance in HCC827 (EGFR exon 19 deletion) cells.; Cheng 2016, PMID 26716514, Oncotarget: VP synergizes with cisplatin, radiation, and ERLOTINIB in NSCLC cells; YAP1 knockdown improves sensitivity to EGFR inhibitor erlotinib; EGFR-mutated or KRAS-mutated NSCLC show higher nuclear YAP1 than EGFR/KRAS-WT NSCLC (n=124 resected specimens).; Park 2021, PMID 33486901, Cancer Med: VP effectively causes death of EGFR-TKI-RESISTANT lung adenocarcinoma cells (PC9/GR, HCC827/GR) by ...

Ivermectin exhibits meaningful cancer selectivity through multiple converging mechanisms: (1) Selective synergy on cancer cells with sparing of normal fibroblasts — Asano et al. 2025 (PMID 41318162) showed IVM IC30 was 2.08 μM for A549 lung-cancer cells vs. 6.4 μM for normal Hs27 fibroblasts (3-fold selectivity window); triple-combination (rMETase + cisplatinum + IVM) at A549 IC30 concentrations essentially eradicated A549 cells with minimal effect on Hs27 fibroblasts. (2) Platelet-membrane camouflaged ivermectin nanocrystals achieved IC50 2.89 µg/mL on MDA-MB-231 with cytocompatibility on normal fibroblasts (PMID 41495333). (3) Cancer-specific addictions exploited: EGFR-mutant NSCLC is uniquely vulnerable to EGFR-binding (Jiang 2019), PAK1-Stat3-IL-6 axis blockade (Kim 2019), and mitochon...

DIRECT NSCLC EVIDENCE: Three PubMed-indexed studies provide direct NSCLC evidence, of which two measure NSCLC-relevant CSC-adjacent readouts: (1) Malak et al. 2025 (PMID 40174264, Tissue Cell) — urethane-induced NSCLC BALB/c mouse model, oral IVM 5 mg/kg/day suppressed EGFR/PI3K/AKT/mTOR/VEGF, reduced Ki-67, increased BAX/Bcl-2 ratio and active caspase-3 (NSCLC in vivo, NOT EGFR-exon-20 specific, NOT CSC-marker stratified). (2) Hayashi et al. 2024 (PMID 39626921, Anticancer Res) — NSCLC A549 cells + paclitaxel, IVM abolished P-gp induction via EGFR/ERK/Akt/NF-κB; no CSC markers measured. (3) Asano et al. 2025 (PMID 41318162, Anticancer Res) — A549 lung-adenocarcinoma cells, IVM IC30 = 2.08 μM (selective vs. Hs27 fibroblasts IC30 = 6.4 μM); triple-combination with rMETase (targeting methion...

DIFFERENTIAL PROFILE IS INDIRECT AND MODEST. NKCP/NKase is NOT a cytotoxic chemotherapy — its core activity is enzymatic (serine-protease fibrinolysis, ECM remodeling, Nrf2/HO-1 antioxidant induction). In HEALTHY subjects, oral NKCP at 250 mg/day is well tolerated and produces beneficial effects on blood flow (reduced neck/shoulder stiffness, headache, low-back pain, extremity coldness) without adverse events in two double-blind RCTs (PMIDs 29415906, 25653551). Nattokinase is generally recognized as safe (GRAS) for use as a food-grade enzyme and has a favorable hemorrhagic-safety margin vs t-PA (standard safety margin 4.0 for NKase vs 1.2 for t-PA in a carotid-thrombosis model — Guo 2019, PMID 31695953). In CANCER: NKase acts primarily as a TME-modulating adjuvant — degrading tumor fibrone...

DIRECT EVIDENCE IN NSCLC (and specifically EGFR exon 20 NSCLC CSC metabolism) IS ABSENT in the PubMed-indexed literature as of search date (Aug 2026). No paper combines 'nattokinase' OR 'NKCP' with 'EGFR exon 20', 'NSCLC cancer stem cell', 'ALDH', 'CD133', 'CD44 NSCLC', or 'cancer stem cell metabolism' in a single study. INDIRECT EVIDENCE that supports mechanistic plausibility: (1) NKase-mediated ECM remodeling (fibronectin degradation, CAF inactivation, hypoxia alleviation) is well established across multiple solid tumor types (breast, colon, HCC — PMID 37057972, PMID 41021005, PMID 31370114) and is tumor-agnostic in principle, applicable to EGFR exon 20 NSCLC stroma. (2) Direct suppression of CSC markers CD44 and vimentin by oral NKCP-family extract in HCC mice (PMID 31370114) is the clo...

Bromelain shows differential cytotoxicity favoring cancer cells. In normal human PBMCs, bromelain at 0-120 µg/mL exhibited LOW overall cytotoxicity, did not cause non-specific proteolysis of cellular proteins, and triggered apoptosis only at the highest doses (60 µg/mL: 9.8%; 120 µg/mL: 15.08%) with maximum DNA damage of 16% in comet tail (Bernasinska-Slomczewska 2026, PMID 42045533). In contrast, in cancer cell lines bromelain achieves substantial cytotoxicity: IC50 ~2.5 µg/mL in A-549 lung cancer (bromelain-conjugated gold nanoparticles, PMID 31554850); IC50 8.8 mg/mL in Caco-2 colon cancer (PMID 36837502); significant cytotoxicity in HN5 oral SCC (PMID 36506883), CRC (PMID 37262048), cholangiocarcinoma (PMID 26935541), and GI cancer cells (PMID 25425315). In Kiperin Bromelain & Papain c...

DIRECT NSCLC EGFR exon 20 CSC-metabolism evidence: NONE. No PubMed-indexed study directly examines bromelain in EGFR exon 20 insertion-mutant NSCLC, and no study measures CSC metabolic readouts (OCR/ECAR, OXPHOS, glycolysis, glutaminolysis, FAO, PPP flux, metabolomics) in response to bromelain in any NSCLC context. INDIRECT but mechanistically convergent evidence supporting a hypothesis for efficacy in EGFR exon 20 CSC metabolism: (1) DIRECT LUNG CANCER EVIDENCE — Majumder 2021 (PMID 33893581) bromelain + olive leaf extract reduced benzo(a)pyrene-induced lung carcinogenesis via Nrf2 activation + NF-κB suppression + ↓TNFα/IL-6/MMPs in lung tissue; Batkin 1988 (PMID 3182910) bromelain decreased Lewis lung carcinoma lung metastasis in mice; Iram 2019 (PMID 31554850) bromelain-conjugated gold ...

Spermidine has a uniquely paradoxical cancer-vs-healthy profile that is heavily concentration-, route-, and context-dependent. (1) ENDOGENOUS LEVELS: spermidine and total polyamine pools are typically elevated in cancer cells vs healthy counterparts (polyamines are required for sustained proliferation); ODC1 is a MYC target and is co-amplified in aggressive tumours — but in NSCLC specifically, plasma spermidine levels are LOWER in early-stage lung cancer patients vs controls (Liang 2022, PMID 34794861), making it a diagnostic biomarker. (2) SUPPLEMENTATION CONTEXT: dietary/exogenous spermidine is widely promoted for longevity, cardioprotection and cancer chemoprevention (Madeo lab); however Tahara 2025 (PMID 41408852) demonstrates that low-dose SPD (<20 μM) is DHPS-dependent proliferative ...

direct_nsclc_evidence: Multiple NSCLC-specific spermidine/polyamine pathway papers exist but NONE directly test NSCLC cancer stem cells (CSCs): (1) Martin-Martin et al., Biol Res 2026 (PMID 41715254) — SAM486A (AMD1/polyamine inhibitor) + adagrasib in KRASG12C NSCLC (H1299, H23, H2009, LLC46, LL2) — antiproliferative synergy but no CSC markers measured. (2) Men et al., Cancer Sci 2025 (PMID 40485050) — dauricine + osimertinib (3rd-gen EGFR-TKI) overcame osimertinib resistance in NSCLC cell lines and patient-derived organoids via SAT1 stabilisation; no CSC-marker analysis but ferroptosis-relevant. (3) Wu et al., Transl Lung Cancer Res 2024 (PMID 39830759) — miR-9-3p/SAT1/p53 axis in LUAD; ferroptosis focus, no CSC panel. (4) Han et al., PNAS 2024 (PMID 38513095) — SAT1 activation in lung ca...

Preferential cytotoxicity toward malignant cells is suggested but inconsistent. In vitro, bromelain is antiproliferative against multiple tumor cell lines (glioma, breast, ovarian, prostate, colon, CML, HepG2 HCC, HL-60 leukemia, Caco-2 colon) while showing minimal toxicity in normal human PBMCs, keratinocytes, and mononuclear leukocytes (Ataide 2021, PMID 33986357; Taskin 2019, PMID 31998459; Pakbin 2023, PMID 36837502). The combination idarubicin + bromelain produced less genotoxicity in normal PBMCs than in HL-60 cancer cells (Taskin 2019, PMID 31998459), implying a therapeutic window. In healthy individuals, PERT/Wobenzym is generally well tolerated — main adverse events are gastrointestinal (diarrhea, meteorism, flatulence, dyspepsia) — and large post-marketing studies (n=640 cystitis...

DIRECT evidence for PERT/Wobenzym affecting NSCLC EGFR exon-20 CSC metabolism is essentially absent. PubMed searches combining 'pancreatic enzyme' OR 'Wobenzym' OR 'systemic enzyme' OR 'proteolytic enzyme' with 'NSCLC', 'EGFR exon 20', or 'cancer stem cell' returned no primary NSCLC-CSC interventional study. INDIRECT mechanistic plausibility exists via three converging lines: (1) The Gremmler 2021 systematic review (PMID 34230116) included lung-cancer patients among its 15 studies (n=3008 total) of oral proteolytic enzyme therapy; subgroup data were insufficient to attribute benefit but confirm safety in the NSCLC context. (2) Bromelain (a Wobenzym component) inhibits NF-κB, Wnt/β-catenin, and VEGF/bFGF pathways — all three are core nodes in NSCLC CSC self-renewal, EGFR-TKI resistance, and...

selectivity: Multiple lines of evidence support preferential cytotoxicity toward cancer cells over healthy cells: (1) A. muricata fruit extract showed 60% MMP-2/MMP-9 inhibition in primary patient-derived tumor cells but only 2% inhibition in matched normal-tissue primary cells (Drishya 2020, PMID 32661216). (2) ALPS (A. muricata leaf polysaccharides) protected cisplatin-treated RAW 264.7 macrophages and bone-marrow-derived macrophages from apoptosis (suppressing Bax/cyt.c/caspase-3/8/9 and restoring MTP) while NOT rescuing A549 or H460 lung cancer cells from cisplatin killing (Han 2023, PMID 36453199) - i.e. ALPS is cytoprotective to normal macrophages while sparing cisplatin's antitumor activity on NSCLC. (3) AME-loaded PLGA/Ge electrospun scaffolds significantly inhibited MCF-7 / MDA-MB...

direct_nsclc_cell_line_evidence: A549 (lung adenocarcinoma, KRAS-G12S, wild-type EGFR): ethyl acetate fractions of A. muricata leaves achieved 99.6% / 99.4% cytotoxicity; active metabolites pheophorbide A and diphenylcyclopropenone (Salac 2022, PMID 36145779).; A549 + H460 (large-cell NSCLC): cisplatin alone or cisplatin + ALPS both showed significant toxicity against these NSCLC lines, while ALPS selectively protected normal macrophages (Han 2023, PMID 36453199) - supports combination strategy.; A549: n-hexane, ethyl acetate and methanol leaf extracts of A. muricata gave the highest growth-inhibitory activity among six plant species screened; phytochemicals docked to EGFR, ERBB2, AKT1, MTOR, KDR, IGF1R, MMP2, MMP9, HRAS cancer biomarkers (Grijaldo 2023, PMID 37332828).; A549: cananginone ...

Krill oil is broadly cytostatic and pro-apoptotic against multiple cancer cell lines and orthotopic tumor models (colorectal, bladder, neuroblastoma, lung, prostate CSC-derived) while being well-tolerated in normal tissue. Acute toxicity tests in xenograft mice showed no significant toxic effects by biochemistry or H&E histology (PMID 35651016). In healthy adult dogs, high-dose EPA+DHA (up to 0.71 g/kg BW^0.75) was well tolerated for 8 weeks, with dose-dependent incorporation into circulating phosphatidylcholine and lysophosphatidylcholine fractions, modest reduction of α-tocopherol (vitamin E) — a signal that concurrent antioxidant supplementation is advisable — but no change in malondialdehyde (lipid peroxidation) or inflammatory cytokines (PMID 42596571). In healthy humans, phospholipid...

direct_krill_oil_in_nsclc: No published study to date has tested krill oil specifically in EGFR exon 20 insertion NSCLC or in NSCLC-derived cancer stem cells. This is a documented evidence gap.; indirect_evidence_chain: link: EGFR pathway suppression by KO in CRC; evidence: Krill oil at 5–15% of dietary intake dose-dependently reduced tumor weight (68.5%) and volume (68.3%) and inhibited EGFR phosphorylation, pEGFR, pAKT, pERK1/2 in CT-26 orthotopic colorectal tumors (PMID 35120511). EGFR is the same oncogenic driver mutated in exon 20 insertion NSCLC, suggesting KO would dampen constitutive EGFR signaling.; link: DHA (the principal bioactive in KO) directly sensitizes EGFR-mutant NSCLC to TKIs; evidence: DHA restored gefitinib sensitivity in PC-9/GR gefitinib-resistant NSCLC cells and pot...

VCO/lauric acid exhibits a dual action profile: preferentially cytotoxic/apoptotic in cancer cells while cytoprotective in normal cells. The cancer-cell selectivity is physical (membrane dynamics — lung cancer cells partition C12SL lauric-acid analog more readily than normal cells, PMID 38234602) and metabolic (CSCs with glycolytic-dominant, low-ROS metabolism are forced into OXPHOS by LA, triggering lethal ROS burst; PMID 39859378, 40076581). In vivo, coconut-oil-based high-fat diets did not accelerate tumor growth in a syngeneic melanoma model, unlike butter/lard/beef-tallow HFDs, and preserved NK/CD8 T-cell infiltration (PMID 40715760). In NNK-induced lung cancer in A/J mice, however, coconut oil alone did not significantly reduce lung tumor nodules, while fish oil (rich in omega-3 PUFA...

direct_vco_in_nsclc_egfr_exon20: No published study to date has tested VCO, lauric acid, or coconut-oil-derived MCTs in EGFR exon 20 insertion NSCLC, in NSCLC-derived cancer stem cells, or in CSC metabolism of exon 20 insertion disease. This is a documented evidence gap.; indirect_evidence_chain: link: NSCLC clinical prognostic association: serum lauric acid predicts nivolumab PFS; evidence: In a 148-patient NSCLC cohort receiving nivolumab (anti-PD-1), elevated pre-treatment serum lauric acid was independently predictive of longer PFS (p=0.015 univariate; p=0.036 multivariate) along with LDL-C and HDL-C, after adjustment for PD-L1 expression (PMID 34091744, Cancer Immunol Immunother 2022). This is the most directly NSCLC-relevant finding: higher endogenous lauric acid levels correlate wit...

L-Carnitine is essential for normal physiology of FAO-dependent tissues (heart > skeletal muscle > liver > kidney); deficiency causes cardiomyopathy, myopathy, hypoketotic hypoglycemia, and encephalopathy. In healthy adults, dietary and endogenous carnitine maintains plasma free carnitine ~40-60 μmol/L; OCTN2/SLC22A5 reabsorbs >95% of filtered carnitine in renal proximal tubule. In healthy HSPCs, L-carnitine is a positive regenerative signal via PPARα-TFEB (PMID 42189862), suggesting physiological roles in stem-cell maintenance beyond FAO substrate. CANCER-SIDE: tumors hijack the carnitine shuttle at multiple nodes — (i) SLC22A5/OCTN2 is upregulated in immunotherapy-resistant NSCLC (PMID 41045681) and in esophageal SCC where its expression predicts oxaliplatin response (PMID 34603016); (ii...

direct_l_carnitine_in_nsclc: No published trial has supplemented L-carnitine or ALC specifically in EGFR exon 20 insertion NSCLC or measured NSCLC CSC markers (ALDH1A1, CD133, CD44) after L-carnitine treatment. This is a documented evidence gap. However, the L-carnitine–CPT1A axis is among the most directly implicated metabolic pathways in NSCLC CSC biology across the recent literature (2024-2026 surge of high-impact papers).; indirect_evidence_chain: link: SLC22A5 (L-carnitine transporter) drives anti-PD-(L)1 resistance in NSCLC (direct NSCLC; immunotherapy-relevant for cold EGFR-exon-20 tumors); evidence: Wang et al. (Drug Resist Updat 2026) dissected OAK (n=699) and POPLAR (n=192) trial data and showed carnitine metabolism is the most prominent metabolic process predicting resistance to...

selectivity_evidence: Sargassum ilicifolium fucoidan is NOT toxic to L929 normal fibroblasts but exhibits cytotoxicity against A549 NSCLC cells (Tsou et al, Sci Rep 2022, PMID 36151104).; Low-molecular-weight fucoidan (LMF) exerts selective cytotoxicity against oral precancerous DOK cells while sparing normal fibroblasts, with stress-adaptive (rather than pro-death) transcriptional response in fibroblasts (Dent Mater J 2026, PMID 42324148).; Fucoidan-coated liposomes showed ~7-fold improved oral bioavailability AND reduced systemic toxicity versus free oxaliplatin in vivo (PMID 42595156).; Oligo-Fucoidan attenuated side effects of olaparib (reduced immunosuppressive M2 macrophages) while enhancing antitumor immunity (PMID 36109724).; HAZ@Fu NPs (hyaluronic-acid-coated fucoidan-zinc) showed...

primary_nsclc_cell_lines_tested: A549 (EGFR wild-type lung adenocarcinoma) — apoptosis, migration, EMT, proteomic CSC-metabolism targets; H1299 (p53-null NSCLC) — fucoidan-trabectedin PLGA NP apoptosis; H1650 (EGFR exon 19 deletion mutant NSCLC, CSC-enriched) — fucoidan mTOR/VEGF/Bax-Bcl-2 effects (Chen et al, PMID 33430854); A549 xenograft nude mice — in vivo tumor reduction (Hu et al, PMID 42392389; Chen et al, PMID 33430854); direct_csc_marker_evidence: Oligo-Fucoidan reduced CD44high/CD24low CSC subpopulation, EpCAMhigh cells, and mammosphere formation (Chen et al, PMID 36109724). CD44 knockdown phenocopies oligo-fucoidan effects (Sci Rep 2017, PMID 28098144).; direct_csc_metabolism_evidence: Fucoidan suppressed glucose uptake and lactate production in tumor cells (PMID 36109724); down...

CRITICAL DICHOTOMY: UA is a CONTEXT-DEPENDENT mitochondrial modulator, not a uniform anti-cancer or anti-aging agent (PMID 42550351, 2026 Mol Biol Rep). In CANCER cells (especially p53-WT or early-stage): UA-induced mitochondrial stress activates tumor-SUPPRESSIVE responses — p53 stabilization, p21/PUMA/NOXA induction, G2/M arrest, apoptosis, glycolysis suppression (TIGAR), EMT reversal, MMP downregulation, immunogenic remodeling. In HEALTHY cells: the SAME mitophagy induction is protective — clears damaged mitochondria, reduces ROS/senescence, preserves function (cardio-, nephro-, neuro-, radioprotection). THE RISK: per the 2026 review (PMID 42550351), in ESTABLISHED TUMORS under hypoxia, nutrient restriction, dormancy, or therapy-induced stress, mitophagy may HELP tumor cells survive — m...

Preferential cytotoxicity toward malignant cells is suggested but inconsistent. In vitro, bromelain is antiproliferative against multiple tumor cell lines (glioma, breast, ovarian, prostate, colon, CML, HepG2 HCC, HL-60 leukemia, Caco-2 colon) while showing minimal toxicity in normal human PBMCs, keratinocytes, and mononuclear leukocytes (Ataide 2021, PMID 33986357; Taskin 2019, PMID 31998459; Pakbin 2023, PMID 36837502). The combination idarubicin + bromelain produced less genotoxicity in normal PBMCs than in HL-60 cancer cells (Taskin 2019, PMID 31998459), implying a therapeutic window. In healthy individuals, PERT/Wobenzym is generally well tolerated — main adverse events are gastrointestinal (diarrhea, meteorism, flatulence, dyspepsia) — and large post-marketing studies (n=640 cystitis...

DIRECT evidence for PERT/Wobenzym affecting NSCLC EGFR exon-20 CSC metabolism is essentially absent. PubMed searches combining 'pancreatic enzyme' OR 'Wobenzym' OR 'systemic enzyme' OR 'proteolytic enzyme' with 'NSCLC', 'EGFR exon 20', or 'cancer stem cell' returned no primary NSCLC-CSC interventional study. INDIRECT mechanistic plausibility exists via three converging lines: (1) The Gremmler 2021 systematic review (PMID 34230116) included lung-cancer patients among its 15 studies (n=3008 total) of oral proteolytic enzyme therapy; subgroup data were insufficient to attribute benefit but confirm safety in the NSCLC context. (2) Bromelain (a Wobenzym component) inhibits NF-κB, Wnt/β-catenin, and VEGF/bFGF pathways — all three are core nodes in NSCLC CSC self-renewal, EGFR-TKI resistance, and...

Selective toxicity demonstrated. Diosmin and diosmetin show low cytotoxicity against normal MRC5 lung fibroblasts while inhibiting A549 NSCLC cells (selectivity index >2 reported for related hesperidin glycosides vs diosmin; Poomipark 2023). Diosmin is essentially non-toxic to normal tissues at therapeutic doses and is clinically approved for chronic venous insufficiency at 500–600 mg/day. In vivo, diosmin protects normal kidney (cyclophosphamide) and heart (doxorubicin) tissues from chemotherapy-induced damage while preserving cytotoxic activity of doxorubicin against MCF-7 breast cancer cells. This favorable therapeutic window supports repurposing as an adjunct to NSCLC chemotherapy.

DIRECT NSCLC EVIDENCE: Strong mechanistic and in vivo evidence in lung adenocarcinoma (PMID 39405613, Phytomedicine 2024) — FAK inhibition by diosmin suppresses NSCLC proliferation and metastasis via Cyclin D1 ubiquitin-proteasome degradation and Snail mRNA destabilization (EMT reversal) in mouse xenografts. Chemopreventive activity against B[a]P-induced lung carcinogenesis in Swiss albino mice (PMID 35920545, 2022). Inhibition of A549 NSCLC migration/invasion in vitro (PMID 37842519, 2023). BRM-dependent blocking of murine lung adenoma development (PMID 24876151, Carcinogenesis 2014). Diosmin was historically co-administered as premedication with docetaxel in NSCLC chemotherapy regimens (PMID 10756559, Rev Mal Respir 2000). CSC EVIDENCE: No direct experimental isolation of NSCLC cancer st...

SELECTIVE CANCER CELL TOXICITY is supported by multiple converging mechanisms: (1) Cancer cells are typically OXPHOS-addicted or rely on elevated mitochondrial membrane potential (ΔΨm) — BBR preferentially accumulates in mitochondria of cells with high ΔΨm (a hallmark of cancer cells vs. quiescent normal cells), allowing selective complex I inhibition and ATP depletion. (2) AMPK activation in cancer cells triggers mTOR inhibition and autophagy in a context where anabolic demand is high, leading to growth arrest; in normal cells AMPK activation is cytoprotective and metabolic-homeostatic. (3) Berberine is clinically used in humans at 500 mg/day for diabetes/metabolic syndrome with an established safety profile; Indena's Berberine Phytosome® showed no observed adverse events in healthy-volun...

DIRECT NSCLC EVIDENCE (multiple primary studies): (a) BBR suppresses A549 and H1299 NSCLC proliferation, colony formation and migration; induces apoptosis via ROS/ASK1/JNK/mitochondrial pathway in a dose- and time-dependent manner (Ann Transl Med 2022, PMID 35571453). (b) BBR chloride downregulates Sin3A → TOP2B → DNA double-strand breaks → apoptosis in A549 cells and in vivo NSCLC xenografts (Cancer Chemother Pharmacol 2020, PMID 32607786). (c) BBR inhibits NSCLC cell growth, invasion and glycolysis via SPC25/NUF2 axis suppression; validated in xenografts (Naunyn Schmiedebergs Arch Pharmacol 2025, PMID 39755832). (d) BBR upregulates miR-19a targeting tissue factor, inducing apoptosis via miR-19a/TF/MAPK axis (Cancer Manag Res 2019, PMID 31695492). (e) BBR + atmospheric pressure plasma syn...

DIFFERENTIAL PROFILE: MCP SELECTIVELY TARGETS Gal-3-DRIVEN PATHOLOGICAL STATES, with broad safety margin established in human clinical trials and GRAS status. In HEALTHY subjects: (i) Oral MCP 14.4 g/day (4.8 g × 3/day) for 6-18 months in phase II prostate cancer trials produced NO grade 3/4 toxicity (Keizman 2021 Nutrients PMID 34959847; Keizman 2024 Nutrients PMID 37630724); (ii) MCP is GRAS-designated by FDA as a dietary supplement; (iii) In healthy volunteers, oral MCP shows <0.01% bioavailability (da Silva 2026 Biomacromolecules, PMID 41873039) — i.e., the vast majority of ingested MCP remains in the gastrointestinal tract, acting locally as a Gal-3 ligand and gut microbiome substrate with minimal systemic exposure. In CANCER: MCP exerts antitumor activity through (a) direct Gal-3 ant...

DIRECT EVIDENCE FOR MCP IN NSCLC EGFR EXON 20 CSC METABOLISM IS ABSENT in the PubMed-indexed literature as of search date (Aug 2026). No paper combines 'modified citrus pectin' OR 'PectaSol' with 'EGFR exon 20', 'NSCLC cancer stem cell', 'ALDH1A1', 'CD133 NSCLC', 'CD44 NSCLC', or 'cancer stem cell metabolism' in a single study. INDIRECT EVIDENCE is STRONG and MULTI-PRONGED: (1) GAL-3 IS OVEREXPRESSED IN EGFR-MUTATED NSCLC — Goto 2024 (Lung Cancer, PMID 38805901) is the SINGLE MOST DIRECT EVIDENCE: in a 722-patient cohort of stage I LUAD, galectin-3 expression was significantly higher in EGFR-mutated papillary predominant adenocarcinoma vs EGFR-WT (p<0.01), and EGFR-mutated PPA showed worse 5-yr RFS (70.6% vs 83.3%, p=0.03). This identifies Gal-3 as a key mediator of EGFR-mutated NSCLC prog...

Gossypol is broadly cytotoxic to a wide range of cancer cell lines (NSCLC, SCLC, glioma, prostate, breast, cervical, colorectal, leukemia, lymphoma, head & neck, pancreatic, hepatocellular) with IC50 typically in the low-micromolar range (e.g., ~2.4 µM for racemic gossypol in A549; ~82–190 nM for (-)-gossypol in Pluronic P85 micelles in A549). In healthy/normal cells, gossypol has documented toxicities that define its therapeutic window: (1) Male reproductive toxicity — gossypol was originally developed as a male oral contraceptive in China (a property of sustained use); it inhibits sperm motility and dehydrogenase enzymes in spermatocytes. (2) Hepatotoxicity at high doses — phase I dose-escalation established the MTD/RP2D of AT-101 with cisplatin/etoposide at 40 mg BID on days 1–3 of a 21...

direct_gossypol_in_nsclc: Gossypol/AT-101 has been extensively studied in NSCLC: 5 preclinical papers in EGFR-mutant NSCLC cell lines (H1975, HCC827, A549, H1299, NCI-H460), 2 NSCLC xenograft combination studies (cisplatin, gefitinib), 2 randomized NSCLC clinical trials (gossypol + docetaxel/cisplatin in APE1-high advanced NSCLC; AT-101 + docetaxel in advanced NSCLC), 1 phase I trial (AT-101 + cisplatin/etoposide) that included NSCLC patients, and 1 systematic review (PMID 35215257) that pooled both NSCLC randomized trials.; egfr_exon20_relevance: Although no published trial has tested gossypol specifically in EGFR exon 20 INSERTION-mutant NSCLC, three lines of evidence make gossypol mechanistically adjacent and uniquely well-suited for this subtype: (1) Direct inhibition of EGFR L858R/T79...

Rhein displays broad preclinical anticancer activity across NSCLC (A549, Lewis lung carcinoma, chemoresistant lung cancer cell lines), melanoma (B16F10), breast cancer (MCF-7, MDA-MB-231), colorectal cancer (CT26, HCT116 peritoneal metastasis), bladder cancer (TRAIL-sensitive and -resistant), oral cancer (CAL-27), osteosarcoma, leukemia (AML), hepatocellular carcinoma, gastric cancer, pancreatic adenocarcinoma, and glioma—typically with IC50 values in the 25–100 μM range as free drug and low-micromolar (5–10 μM) when delivered as nanomedicine or PROTAC conjugate (e.g., Rhein-PROTAC D9 IC50 = 5.88 μM in A549 vs 88.45 μM for free rhein; PMID 38818648). In healthy/normal cells, rhein's dose-limiting toxicities are well-characterized: (1) Gastrointestinal—diarrhea, abdominal cramping, nausea, ...

direct_rhein_in_nsclc: Rhein has been directly tested in NSCLC cell lines and tumor models in multiple studies: (1) Direct inhibition of proliferation/migration of chemosensitive AND chemoresistant lung cancer cell lines via Stat3/Snail/MMP2/MMP9 (PMID 35178453). (2) Rhein-based PROTAC D9 in A549 NSCLC, IC50 = 5.88 μM (15-fold more potent than free rhein), inducing VEGFR-2 degradation, apoptosis, and G1 cell-cycle arrest (PMID 38818648). (3) Rhein preserved cisplatin antitumor efficacy in A549 NSCLC cells and Lewis lung carcinoma (LLC) tumor-bearing mice while protecting against cisplatin-induced AKI (PMID 40469629). (4) Network pharmacology of Radix Rhein Et Rhizome identified rhein as the core component interacting with 50 cross-validated targets, with hub genes enriched in oxidative-str...

XN exhibits a therapeutically useful therapeutic window. Multiple reviews and primary studies report that XN selectively targets cancer cells while sparing normal cells; human subject studies show it is safe and well tolerated, with reductions in oxidative DNA damage and inflammatory cytokines. In membrane/cytotoxicity screens (Stompor-Gorący et al., 2026), XN analogues were antiproliferative against 11 human + 1 murine cancer lines in the low-µM range, while hemolytic activity against human erythrocytes was only seen at ≥100 µM (and the dihydro-derivatives DHXHC/DHXHK were only 'slightly toxic' to erythrocytes even at 100 µM). In NSCLC, the XN@CuO/HA nanobipyramid formulation showed 'excellent biosafety' in C57BL/6 mice with potent anti-tumor efficacy. The cancer-selectivity is believed t...

Direct evidence in EGFR exon 20-insertion NSCLC cancer stem cells is NOT yet available; the literature supports mechanistic plausibility through convergent findings across NSCLC and CSC-relevant models. NSCLC-specific primary evidence: (1) Jiang et al., 2026 (PMID 41809377, Mater Today Bio) developed XN-coordinated copper oxide/hyaluronic-acid nanobipyramids (XN@CuO/HA) as a 'cuproptosis inducer for non-small cell lung cancer (NSCLC) therapy', showing potent in-vitro antitumor activity via mitochondrial dysfunction, ROS accumulation, and cuproptosis mediated by the FOXO1-GADD45G axis; in vivo they suppressed LLC xenografts in C57BL/6 mice, remodeled the immunosuppressive TME (↑CD8+ T / NK1.1+ cells, ↓MDSCs), and synergized with anti-PD-1 — all directly relevant to NSCLC immunotherapy resis...

Low-dose aspirin is uniquely positioned among cytotoxic adjuncts because its primary mechanism — irreversible platelet COX-1 acetylation — is essentially inert in non-thrombotic, non-malignant cells, since quiescent platelets do not drive cancer progression. In healthy volunteers, a single 75–100 mg dose inhibited systemic PGE2 biosynthesis by ≈45% (P<0.0001) without measurable effects on tissue-resident nucleated cell function (because their COX-2 is resynthesized within hours) (PMID 27554763). Cancer cells are disproportionately dependent on COX-2-derived PGE2 (for proliferation, EMT, angiogenesis, immune evasion) and on platelet cloaking (for survival in circulation); both dependencies are selectively abrogated by low-dose aspirin. At supra-therapeutic doses (≥2 mM in vitro — well above...

direct_aspirin_in_nsclc_csc: Multiple direct lines of evidence document aspirin's action on NSCLC cancer stem cells (CSCs) and CSC-relevant phenotypes: (1) Khan et al. 2019 (PMID 31729456) directly studied aspirin in NSCLC CSC-enriched spheroids and demonstrated mTOR transcriptional repression → Akt/GSK3β/Snail/β-catenin axis → EMT reversion — the canonical anti-CSC mechanism. (2) Chen et al. 2019 (PMID 30878308) directly measured ALDH+ CSCs in A549 NSCLC under hypoxia and showed aspirin inhibits hypoxia-enhanced stemness, sphere formation, and exosomal HIF-1α/COX-2/miR-135b/miR-210 cargo. (3) Li et al. 2020 (PMID 31993373) explicitly demonstrated that aspirin overcomes acquired EGFR-TKI resistance in NSCLC by suppressing both enhanced cancer stemness and activated NF-κB — directly tying a...

selective_cancer_cytotoxicity: HeLa cervical cancer IC50 0.16 mg/mL (48 h) / 0.19 mg/mL (24 h) — pro-apoptotic via Caspase 3/7 + migration inhibition (PMID 35473537, Anticancer Agents Med Chem 2022).; PEG-L-cit HSA-baicalein NP IC50 5.42 µg/mL in HCT-116 colon cancer cells while maintaining safety toward normal lymphocytes (PMID 41488536, RSC Adv 2026).; ADI-PEG20 (depletes L-arg, raises L-cit) selectively kills ASS1-deficient arginine-auxotrophic cancer cells (melanoma, HCC, mesothelioma, pancreatic, subset NSCLC); normal cells with intact ASS1 are spared (PMID 34920062, PMID 36227339, PMID 31823161).; In CMT167 murine lung adenocarcinoma, anti-PD-1 + L-arg + L-cit reduced tumor volume 5.8-fold vs control without reported normal-tissue toxicity (PMID 40809234, J Thorac Dis 2025).; healthy...

direct_nsclc_evidence: PMID 40809234 (J Thorac Dis 2025, Miyamoto N et al.) — CMT167 murine lung adenocarcinoma subcutaneous model: anti-PD-1 + arginine + citrulline combination reduced tumor volume to 198 mm³ vs control 1162 mm³ (P<0.001), vs anti-PD-1 alone 427 mm³, vs anti-PD-1+arg 452 mm³. Progression-free survival significantly improved (P<0.001). Tumor-infiltrating CD8+ lymphocytes: 46.6 cells/hpf (triple combo) vs 24.2 (control), 29.2 (anti-PD-1), 34.3 (anti-PD-1+arg). Mechanism: CD8+ TIL recruitment to TME. This is the MOST DIRECT NSCLC + L-cit study, but uses CMT167 (KRAS-G12D-mutant, not EGFR exon 20 insertion), and no CSC markers measured.; PMID 38566102 (J Transl Med 2024, Luo WC et al.) — Prospective cohort of 74 advanced EGFR+ NSCLC patients on immunotherapy (ICIs), with seri...

Okra preparations exhibit a documented tumor-selective therapeutic window. (1) Lectin-level selectivity: AEL significantly reduced viability of HeLa and T84 cancer cells (MIC 20 µg/ml; 30–40% viability reduction at 100 µg/ml) but had an 'insignificant effect on ACHN adenocarcinoma cell lines' and 'no significant effect … on normal control human cell lines HEK293 (human embryonic kidney cells)' (Gakhar et al., PMID 40849769), a selectivity attributed to differential surface glycosylation between transformed and non-transformed cells that AEL recognizes via its galectin-mimetic lactose/galactose specificity. (2) Flavonoid-level selectivity: okra-derived Q3G, Q3S, ISO and Q3M inhibited NCI-N87, A375 and A549 cancer cell proliferation at 25–100 µmol/L, whereas normal HFLS-RA fibroblast-like sy...

Direct evidence in EGFR exon 20-insertion NSCLC cancer stem cells is NOT yet available; however, the literature provides convergent mechanistic evidence across NSCLC cell lines and CSC-relevant pathways. NSCLC-specific primary evidence: (1) Yang et al., 2022 (Metabolites, PMID 35736417) directly demonstrated that okra-derived flavonoids Q3G, Q3S, ISO and Q3M (25–100 µmol/L) significantly inhibit A549 human lung adenocarcinoma cell proliferation — A549 is the canonical EGFR-wild-type NSCLC line used as the standard screening backdrop for EGFR-targeted agents. (2) Devanesan & AlSalhi, 2021 (Int J Nanomedicine, PMID 34017172) reported that silver nanoparticles green-synthesized from A. esculentus flower extract (AME-AgNPs) exhibited 'in vitro cytotoxic and antiproliferative studies against ca...

summary: γ/δ-Tocotrienols display robust, reproducible CANCER-SELECTIVE cytotoxicity across >10 cancer types at low-µM concentrations (IC50 typically 3–15 µM), while sparing or even protecting normal cells (osteoblasts, neurons, retinal cells, hepatocytes, normal epithelium) at the same or higher doses. In healthy physiology, tocotrienols function as lipid-soluble chain-breaking antioxidants, neuroprotectants (anti-Parkinson, anti-6-OHDA), bone-anabolic agents (stimulate osteoblast proliferation, differentiation, migration via Wnt/β-catenin in normal MC3T3-E1 and BMSC), anti-inflammatory mediators (suppress NF-κB, NLRP3, IL-6, COX-2, 5-LOX), and radioprotectants (mitigate mitochondrial dysfunction). The cancer-selectivity is best demonstrated in PMID 33579452 (TRF+cisplatin in A549 vs HEK2...

direct_evidence: ONE direct NSCLC in vitro study located: Raviadaran et al., 2021 (PMID 33579452, Mater Sci Eng C) — tocotrienol-rich fraction (TRF) + caffeic acid (CA) in W/O/W multiple nanoemulsion synergistically enhanced cisplatin cytotoxicity in A549 human lung adenocarcinoma cells: late-apoptotic phase +23.1%, ROS generation +16.9%, G0/G1 cell-cycle arrest; cell death in A549 achieved. Critically, the TRF:CA:CIS combination simultaneously rescued normal HEK293 cells from cisplatin toxicity (>95% viability vs ~33% with cisplatin alone). This is the single direct in vitro NSCLC efficacy + cancer-vs-healthy selectivity study for tocotrienols located in this PubMed search.; indirect_evidence: IL-6/JAK/STAT3 direct inhibition by γ-T3 (PMID 36126500, Mol Immunol 2022) — the JAK/STAT3 axis ...

Choline is essential in both healthy and cancer cells, but the flux is qualitatively and quantitatively different. HEALTHY CELLS: choline acquired via diet (eggs, liver, soy lecithin) and FLVCR1-mediated import; flux is buffered by PCYT1B (p53-driven) during choline starvation; PEMT (liver) provides an alternative PE→PC route; choline is partly oxidized to betaine for one-carbon metabolism; PC/PE ratio and ER-membrane lipid saturation are tightly regulated; total choline (tCho) MRS signal is low. CANCER CELLS: CHKA overexpression in 40–60% of tumors drives PCho accumulation → elevated tCho MRS signal (a 'metabolic hallmark of cancer'); PCYT1A is activated during autophagy and drug-induced stress; CHKB (choline kinase β) is a component of a 4-gene NSCLC prognostic signature; CHKα2 acquires ...

DIRECT NSCLC CSC EVIDENCE: No published in-vitro or in-vivo study has specifically tested Alpha-GPC or CDP-Choline in EGFR exon 20 insertion-mutant NSCLC cancer stem cells (CSCs). However, multiple lines of mechanistic evidence converge on the relevance of choline/Kennedy pathway to NSCLC CSC metabolism: (1) NSCLC CHKA & prognosis — ChoKα expression is an independent prognostic factor for early-stage NSCLC patients (Ramírez de Molina et al. 2007, cited in PMID 21035492, Adv Enzyme Regul 2011). ChoKα is overexpressed in NSCLC tumors vs normal lung. (2) NSCLC CHKB prognostic signature — Xiao et al. (2024, PMID 38730286, J Transl Med) screened choline metabolism-related genes in 277 advanced NSCLC patients receiving first-line immunotherapy and identified a 4-gene prognostic signature inc...

MIXED/QUALIFIED — curcumin is NOT selectively cytotoxic to cancer cells vs healthy cells. PMID 22156994 (Alexandrow 2012) explicitly tested curcumin C3 complex in BOTH normal (immortalized) human bronchial epithelial AALE cells AND H441 lung adenocarcinoma cells — curcumin INHIBITED STAT3 phosphorylation in BOTH, with reduction in proliferative capacity (Cyclin D1, Mcm2) in BOTH cell types. This is the KEY cancer-vs-healthy distinction paper and shows curcumin's anti-NF-κB/STAT3 action is NOT cancer-selective. TUMOR-PROTECTIVE PARADOX: As an antioxidant/NF-κB inhibitor, curcumin could theoretically protect cancer cells from pro-oxidant chemo- or radiotherapy. EMPIRICAL EVIDENCE IN NSCLC MITIGATES THIS CONCERN: (a) curcumin REVERSES cisplatin resistance in A549/DDP (PMID 22483553) via HIF-1...

summary: Calcium is an essential mineral for healthy bone mineralization, neuromuscular function, and intracellular second-messenger signaling; the RDA is ~1000–1200 mg/day in adults. In HEALTHY physiology, calcium supplementation is used to prevent/treat osteoporosis, hypocalcemia, and muscle cramping; risk of excessive supplementation includes hypercalcemia, vascular calcification, nephrolithiasis, and possible cardiovascular events (controversial). In CANCER biology the picture is reversed: intracellular Ca²⁺ signaling is a well-validated PRO-TUMORAL axis in NSCLC — driving proliferation, migration, invasion, stemness, vasculogenic mimicry, drug resistance (MDR/TKI resistance) and stem-cell-like transformation. The peer-reviewed direction of drug development is therefore calcium-channel...

direct_evidence: ZERO direct peer-reviewed evidence on Maragen / SAC Calcium / 'surface activated calcium' in NSCLC, EGFR exon 20 NSCLC, or any cancer stem cell (CSC) model — confirmed by zero-hit PubMed searches on the quoted brand/identity terms.; indirect_evidence: ITPR3-mediated ER Ca²⁺ release drives NSCLC stemness + vasculogenic mimicry (PMID 42562338) — directly relevant to NSCLC CSC niche.; Piezo1 mechanosensitive Ca²⁺ channel drives circulating tumor cell acquisition of stem-cell-like properties via Ca²⁺ signaling (PMID 41964669) — directly relevant to CSC metastatic biology.; CAMK2 (downstream of Ca²⁺/calmodulin) regulates tumor stem cells in NSCLC (PMID 42066831) — directly relevant to CSC regulation.; TRPML3 lysosomal Ca²⁺ channel drives osimertinib (EGFR-mutant TKI) resistance...

selectivity_summary: WA demonstrates preferential cytotoxicity to cancer vs. normal cells across multiple in-vitro and in-vivo studies. The mechanistic basis for this selectivity includes: (1) Cancer cells typically have higher baseline ROS and lower redox-buffering reserve, making them more vulnerable to WA-induced oxidative stress (further ROS elevation tips them over the apoptotic threshold while normal cells are protected by Nrf2-mediated ARE induction). (2) Cancer cells upregulate vimentin, NF-κB, STAT3, and proteasome activity — WA's direct targets — whereas normal epithelial cells express low vimentin and rely less on constitutive NF-κB. (3) Cancer cells frequently exhibit defective p53 / FOXO tumor-suppressor pathways that WA restores. (4) Cancer mitochondria have higher membrane p...

direct_nsclc_clinical_trial: pmid: 41685666; journal: Integr Cancer Ther; year: 2026; title: Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [(18)F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for As...; relevance: Phase 1 open-label dose-escalation trial of RH324 (ReHeva Biosciences, Columbus, OH), a pharmaceutical-grade Withania somnifera leaf extract FDA-allowed for clinical development as a botanical oncology drug, in advanced NSCLC patients. The trial uses [18F]FDG-PET/CT as a short-term metabolic biomarker of response — directly assessing the metabolic effect of WA-rich extract on NSCLC tumor glucose uptake. This is the most direct clinical evidence linking WA-class therapy to NSCLC metaboli...

selective_cancer_cytotoxicity: NSCLC cancer-specific window: in paired human small airway epithelial cells (HSAEC) vs lung adenocarcinoma A549 cells, PG reduced A549 viability ~4-fold more than HSAEC; PG was ~1.7× more toxic to A549 than docetaxel/paclitaxel/doxorubicin and ~2.5× more protective of HSAEC than these standard drugs — establishing PG as a 'smart chemotherapeutic' with cancer-selective activity in NSCLC (Davient 2018, PMID 30568916, Front Oncol).; Lung adenocarcinoma A549 vs bone marrow stem cells: prodigiosin analogue PGA from Serratia marcescens SCQ1 showed significant cytotoxicity against A549 (IC50 ≈ 2.2 mg/L ≈ ~5 µM) with LITTLE effect on human bone marrow stem cells in vitro (Zhou 2010, PMID 20717667, Appl Microbiol Biotechnol).; SCLC GLC4 vs GLC4/ADR (doxorubicin-resist...

direct_nsclc_evidence: PMID 30568916 (Davient B et al., Front Oncol 2018; Singapore/NTU + Southern Medical University Shunde) — MOST DIRECT NSCLC cancer-specific study. PG (1 µM × 24 h) reduced A549 (lung adenocarcinoma) viability 4-fold more than HSAEC (primary human small airway epithelial cells); PG was 1.7× more cytotoxic to A549 and 2.5× more protective of HSAEC than docetaxel/paclitaxel/doxorubicin. RNA-seq: in A549, DNA-replication genes DOWN; lipid/cholesterol-biogenesis genes UP (suggesting autophagy-triggering metabolic rewiring); in HSAEC, balanced oncogene + tumor-suppressor co-upregulation conferring survival. The 1:1 ED50 PG+DTX/PTX/DOX combinations were NOT synergistic. Conclusion: 'PG appears to be a smart chemotherapeutic agent that may be both safe and effective for NSCLC...

Preferential cytotoxicity toward malignant cells is suggested but inconsistent. In vitro, bromelain is antiproliferative against multiple tumor cell lines (glioma, breast, ovarian, prostate, colon, CML, HepG2 HCC, HL-60 leukemia, Caco-2 colon) while showing minimal toxicity in normal human PBMCs, keratinocytes, and mononuclear leukocytes (Ataide 2021, PMID 33986357; Taskin 2019, PMID 31998459; Pakbin 2023, PMID 36837502). The combination idarubicin + bromelain produced less genotoxicity in normal PBMCs than in HL-60 cancer cells (Taskin 2019, PMID 31998459), implying a therapeutic window. In healthy individuals, PERT/Wobenzym is generally well tolerated — main adverse events are gastrointestinal (diarrhea, meteorism, flatulence, dyspepsia) — and large post-marketing studies (n=640 cystitis...

DIRECT evidence for PERT/Wobenzym affecting NSCLC EGFR exon-20 CSC metabolism is essentially absent. PubMed searches combining 'pancreatic enzyme' OR 'Wobenzym' OR 'systemic enzyme' OR 'proteolytic enzyme' with 'NSCLC', 'EGFR exon 20', or 'cancer stem cell' returned no primary NSCLC-CSC interventional study. INDIRECT mechanistic plausibility exists via three converging lines: (1) The Gremmler 2021 systematic review (PMID 34230116) included lung-cancer patients among its 15 studies (n=3008 total) of oral proteolytic enzyme therapy; subgroup data were insufficient to attribute benefit but confirm safety in the NSCLC context. (2) Bromelain (a Wobenzym component) inhibits NF-κB, Wnt/β-catenin, and VEGF/bFGF pathways — all three are core nodes in NSCLC CSC self-renewal, EGFR-TKI resistance, and...

Osthole displays a striking, well-documented context-dependent therapeutic window — it is broadly pro-death in cancer cells while cytoprotective in stressed normal cells. CANCER (pro-death): in A549 NSCLC OST inhibits proliferation, induces G1 or G2/M arrest, causes mitochondrial dysfunction (↓ΔΨm, ↑ROS), triggers caspase-9/3 cleavage and apoptosis, and inhibits migration/invasion/colony formation (PMIDs 33014717, 40913911, 42555991, 37436082); in KRAS-mutant CRC OST induces ferroptosis via AMPK/Akt/mTOR suppression (PMID 37318525); in HeLa cervical cancer OST induces autophagy-dependent ferroptosis via TFR1 (PMID 40446951) and Wnt/β-catenin suppression (PMID 34539807); in ESCC OST induces apoptosis via PTEN/PI3K/AKT (PMID 29579711); OST-loaded iron-MOF nanozyme drives immunogenic ferropto...

DIRECT NSCLC EVIDENCE: (1) Abosharaf et al., 2020 (Biotechnol Rep; PMID 33014717) — grapefruit-derived osthole competitively inhibits HDACs (Ki = 3.36 mM) and induces time- and concentration-dependent apoptosis (with ↑caspase-9) in A549 human lung cancer cells — the cleanest single-agent anti-NSCLC primary study. (2) Xu et al., 2025 (Biomed Pharmacother; PMID 40913911) — osthole reverses Cu-promoted A549 NSCLC malignancy: downregulates PGC-1α (mitochondrial biogenesis master regulator), upregulates STAT1/TNF-α/IL-2, causes severe mitochondrial degenerative changes, G1 arrest and apoptosis — directly targets mitochondrial metabolic dependence. (3) Xu et al., 2026 (Phytomedicine; PMID 42555991) — osthole + matrine suppress lead-exposed A549 NSCLC malignant progression: PI3K/AKT and apoptosis...

EGCG displays a well-documented cancer-selective therapeutic window arising from multiple convergent mechanisms. (1) 67LR-overexpression selectivity: 67LR (RPSA) is dramatically overexpressed on tumor cells and CSCs but not on normal cells; EGCG-67LR engagement therefore triggers apoptotic / cAMP-PKA-PP2A-MYPT1-MRLC / AMPK-mTOR-ULK1 cascades preferentially in 67LR-high tumor cells (Fujimura et al., Molecules 2022, PMID 36014370; Hayashi et al., J Nutr Biochem 2022, PMID 35977663). EGCG-PEG-modified liposomes show 'superior antitumor activity against high 67LR-expressing tumor cells' with dual oncolytic + targeting effects. (2) Differential redox handling: in normal cells EGCG acts as a cytoprotective antioxidant (activates Nrf2/HO-1/NQO1, scavenges ROS, protects against ischemic stroke, AK...

Direct EGCG evidence in NSCLC cancer stem cells is substantial and convergent — placing EGCG among the few dietary polyphenols with mechanistically delineated, lung-CSC-specific, primary-research backing. PRIMARY DIRECT EVIDENCE: (1) Jiang et al., Int J Mol Med 2020 (PMID 33125096) — THE single most directly relevant study: EGCG inhibited self-renewal of A549 and H1299 lung cancer stem-like cells (sphere formation + CD133+ FACS-isolated) by repressing CLOCK expression; EGCG decreased CD133+ ratio, reduced CD133/CD44/SOX2/Nanog/OCT4 CSC markers, inactivated Wnt/β-catenin, and in xenografts suppressed CSC-like characteristics of lung cancer cells by targeting CLOCK. (2) Zhang et al., Oncogene 2026 (PMID 42493544) — established NF-κB/ALDH1A1 feedback loop as the master non-mutational EGFR-TKI...

SELECTIVITY PROFILE: Shikonin displays preferential cytotoxicity toward cancer cells over normal cells, with documented selectivity index (SI) values reported across multiple studies. (i) In OSCC benzyl-naphthoquinone analogue screening, shikonin itself showed SI ≥ 3 across OSCC cell lines (compound 1 of Marconi-Nicolau et al., Biomedicines 2026, PMID 42072298) and minimal hemolysis in human erythrocytes + no evident acute adverse effects in mice at tested doses. (ii) In cisplatin-resistant ovarian cancer, the shikonin-copper HS-Cu@DOX nanoplatform 'maintains potent antitumor efficacy while reducing systemic toxicity' — explicitly engineered to spare normal tissue (PMID 42473540). (iii) The 6-O-carboxypropyl-α-tocotrienol + bortezomib combination (which acts via similar ER stress / proteas...

DIRECT NSCLC CSC EVIDENCE: (1) Huang et al., Int J Mol Sci 2024, PMID 38203787 — GOLD-STANDARD CSC STUDY in chemoresistant NSCLC: shikonin inhibits spheroid formation in ABCB1-dependent docetaxel-resistant A549/D16 and ABCB1-independent vincristine-resistant A549/V16; downregulates pluripotency factors Nanog and Oct4 (mRNA + protein); mechanism via PI3K/Akt/p70s6k downregulation; synergistic with BEZ235 dual PI3K-mTOR inhibitor. Quote: 'low doses of shikonin inhibit the proliferation of lung cancer stem-like cells by inhibiting spheroid formation...shikonin's anti-drug resistance and anti-cancer stem cell activities make it a highly interesting molecule for future combined lung cancer therapy.' (2) Cao et al., Eur J Med Res 2024, PMID 39702296 — EGFR-T790M H1975 NSCLC: shikonin overcomes E...

cancer_activity: Fisetin has demonstrated preclinical anticancer activity in NSCLC (A549 — ~70% growth inhibition with HA-BSA-coated NLC fisetin+flavokawain A formulation, BMC Cancer 2026 PMID 42426658), breast cancer (MDA-MB-231 — glucose-capped fisetin Ag NPs targeting NCL/LDHA/PRDX1, 3 Biotech 2026 PMID 42404972), leukemia (Jurkat + K562 — fisetin + pinocembrin synergistic caspase-8 apoptosis, Int J Mol Sci 2026 PMID 42353336), ovarian cancer (Cell Death Dis 2026 PMID 42026023 — fisetin as senolytic reduces β-catenin/YAP heterogeneity-driven metastatic burden), colorectal cancer (Anticancer Agents Med Chem 2026 PMID 42405384), glioblastoma (Cancers Basel 2026 PMID 42073546 — senolytic anti-recurrence strategy), and tuberculosis lung disease (Nat Commun 2026 PMID 42098153 — fisetin as pa...

direct_nsclc_evidence: ONE published direct NSCLC fisetin paper retrieved: Hasnain, Telange & Kapoor (BMC Cancer 2026, PMID 42426658) developed hyaluronic-acid–bovine serum albumin (HA-BSA)-coated nanostructured lipid carriers (NLCs) co-encapsulating fisetin + flavokawain A for NSCLC therapy using a Quality-by-Design approach. The optimized formulation (~115 nm particle size, PDI < 0.3, zeta potential ~ −40.8 mV, drug entrapment efficiency ~85.5–89.5%, sustained release ~90–93.8% over 9 h) achieved up to ~70.32% inhibition of A549 NSCLC cells in vitro, significantly greater than free drug. The HA-BSA coating targets CD44 — a well-established NSCLC CSC marker — providing a CSC-targeting rationale even though the authors did not specifically measure CSC markers. This is the only NSCLC direct...

Steviol / stevioside / isosteviol preparations display a consistently documented tumour-selective therapeutic window across multiple in-vitro and in-vivo systems. (1) STEVIOL/ISOSTEVIOL AMMONIUM DERIVATIVES — Voloshina et al. (Bioorg Med Chem 2021, PMID 33461146): lead compounds 4, 5 showed IC50 at doxorubicin level in MCF-7 with selectivity index 5.0–5.2, did NOT cause hemolysis, and showed only SLIGHT cytotoxicity against normal human embryonic lung fibroblasts Wi-38 — explicit demonstration of a therapeutic window between A-549 NSCLC killing and Wi-38 normal-lung-cell sparing. (2) STEVIOL-TPP DUAL CONJUGATE 23d — Li et al. (Eur J Med Chem 2026, PMID 41812408): IC50 = 0.19 µM in Huh7 hepatoma with selectivity index 15.42 against normal hepatocytes — among the highest cancer-vs-normal sel...

Direct evidence in EGFR exon-20 insertion NSCLC cancer stem cells is NOT yet available; however, the literature provides convergent mechanistic evidence across NSCLC cell lines and CSC-relevant pathways. NSCLC-SPECIFIC PRIMARY EVIDENCE: (1) Chen et al. — Int J Biol Macromol 2025 (PMID 40449772): sodium-alginate/poly(N-vinylpyrrolidone) nanogels loaded with rebaudioside A (R), stevioside (S), or R/S mixture showed 52.88–62.13 % cytotoxicity improvement against A549 NSCLC vs free compound, with Topo-II IC50 = 0.95–1.10 µM and DNA-binding IC50 31.5–33.9 µM; VERO normal kidney cells spared (IC50 30.9–46.5 µM) — DIRECT A549 NSCLC evidence. (2) Voloshina et al. — Bioorg Med Chem 2021 (PMID 33461146): steviol/isosteviol ammonium derivatives cytotoxic against A-549 NSCLC with mitochondrial-pathway...

Selective toxicity window is favorable and clinically established. Rare ginsenosides (Rg3, Rh2, Rk1, Rg5) induce apoptosis in NSCLC cell lines (A549, H1975, Calu-3, HCC827, LLC, Ba/F3-EGFR mutants) at low μM concentrations while sparing normal bronchial epithelial cells (BEAS-2B), normal hepatocytes (AML12), MRC5 lung fibroblasts, and H9c2 cardiomyocytes at equivalent doses. In vivo, Rg3 protects normal kidney from cisplatin nephrotoxicity (via SIRT1/NLRP3 suppression, downregulating OCT2 and P-gp in renal tissue) and normal heart from doxorubicin cardiotoxicity (via HDAC8/BRCA2/DRP1 mitochondrial protection) while enhancing the same drugs' antitumor activity in lung cancer models (PMIDs 42169649, 42273332). Shenyi Capsule (oral Rg3) is NMPA-approved and on-market in China since 2000; meta...

DIRECT NSCLC CSC EVIDENCE: STRONG. The most directly on-target paper in the entire PubMed literature is Liu X, et al., J Transl Med 2025 (PMID 41214647) — 'Ginsenoside Rh2 as a novel PIN1 inhibitor disrupting the cancer stem cell-like phenotype in non-small cell lung cancer.' This study demonstrates: (i) Rh2 inhibits CSC-like properties in NSCLC cells using tumor sphere formation assays; (ii) Rh2 reduces stemness-related transcription factors and ALDH+/CD133+ populations; (iii) Rh2 directly binds prolyl isomerase PIN1, disrupting PIN1-PGK1 interaction; (iv) Rh2 reduces PIN1-dependent mitochondrial translocation, phosphorylates PDHK1 at T338, upregulates PDH complex; (v) Rh2 shifts tumor metabolism from aerobic glycolysis to mitochondrial oxidative phosphorylation (Warburg reversal); (vi) R...

SELECTIVE CANCER CELL ACTIVITY is supported by multiple converging lines of evidence: (1) Cancer-specific STAT3 dependence — STAT3 is constitutively active in NSCLC and most solid tumors but is transient/inducible in normal cells; silibinin's primary target (pSTAT3 Tyr705) is therefore selectively pathological. (2) Cancer-specific EGFR overactivation — silibinin binds EGFR but cancer cells rely on EGFR autophosphorylation for survival (especially EGFR-mutant NSCLC), whereas normal epithelial cells with intact ligand-regulated EGFR are less affected. (3) Cancer-specific metabolic rewiring — the HBP/OG-GlcNAc metabolic vulnerability uncovered by CRISPR screening is a cancer-specific phenomenon; normal cells tolerate HBP inhibition better due to alternative metabolic flux. (4) Established cli...

DIRECT NSCLC EVIDENCE (multiple primary studies + clinical): (a) Rugamba et al. (Cells 2021, PMID 34209829): Silibinin inhibits A549, H292, and H460 NSCLC cell proliferation in a concentration-dependent manner, inducing G0/G1 cell cycle arrest and apoptosis, inhibiting tumor angiogenesis/migration/invasion, AND suppressing tumorsphere formation — a direct CSC functional assay. Silibinin binds EGFR, downregulates pEGFR, inhibits JAK2/STAT5/PI3K/AKT, reduces PD-L1, MMP and VEGF; STAT5-PD-L1 promoter complex disrupted — formally proposed as a 'candidate for tumor immunotherapy and cancer stem cell-targeted therapy'. (b) Bosch-Barrera et al. (Front Med 2025, PMID 40703266): First clinical case report of silibinin (630 mg/day oral) + pembrolizumab combination in a 72-year-old male with stage IV...

selectivity_basis: NQO1 expression gradient. NQO1 is barely detectable in normal lung/bronchial epithelium but overexpressed 5–200-fold in NSCLC (incl. EGFR-mutant, KRAS-mutant, and SCC), breast, pancreatic, brain (GBM stem cells) and colon tumors. The NRF2-Keap1 axis, frequently active in NSCLC due to oxidative stress, drives NQO1 transcription.; healthy_cell_treatment: Normal human astrocytes (NHA), BEAS-2B bronchial epithelial cells, and PBMCs are spared because of low NQO1. PBMCs spared in PDAC assays; BEAS-2B used as safety benchmark in NSCLC tanshinone comparator study; NHAs spared in GBM work.; therapeutic_window_challenge: Native β-Lap has poor aqueous solubility, rapid clearance, and a narrow therapeutic window causing hemolysis and methemoglobinemia at high doses. Prodrug (β-Lap-...

direct_evidence_in_nsclc_models: pmid: 42353275; model: Patient-derived LUAD sphere/organoid models; A549 and H1299 (RAS-mutant LUAD); syngeneic KRAS-mut/p53-null mouse lung cancer model; finding: β-Lapachone identified as a potent USP22 inhibitor (IC50 ~0.75 µM); inhibited sphere formation and reduced CD133+ cancer stem cell populations in patient-derived LUAD. Synergized with cisplatin (increased DNA damage and apoptosis). Suppressed tumor growth in vivo and potentiated cisplatin.; relevance_to_egfr_exon20_csc: USP22-driven stemness is a shared axis across EGFR-mutant, KRAS-mutant, and TP53-null NSCLC; β-Lap's USP22 inhibition directly attacks CSC self-renewal independent of the EGFR driver mutation, making it a candidate backbone for EGFR-exon-20-insertion CSC metabolic therapy.; pmid: ...

SELECTIVE CANCER CELL ACTIVITY is supported by multiple converging lines of evidence — but with a CRITICAL CAVEAT that defines azaserine's therapeutic window limitation: (1) CANCER-SPECIFIC GLUTAMINE ADDICTION — Cancer cells (including NSCLC, PDAC, DLBCL, breast) are uniquely dependent on glutamine as carbon/nitrogen source for de novo nucleotide biosynthesis, amino acid synthesis, TCA anaplerosis, glutathione production, and HBP/O-GlcNAc flux; normal cells tolerate glutamine amidotransferase inhibition far better due to lower HBP flux demand and parallel metabolic compensation. (2) DIRECT SELECTIVE-CANCER DEMONSTRATION: Abdelsattar et al. (Int J Mol Sci 2024, PMID 39795937) showed that azaserine at low concentrations potently inhibited MCF-7 breast cancer cell proliferation WITHOUT detect...

DIRECT NSCLC EVIDENCE — MULTIPLE PRIMARY STUDIES + MECHANISTICALLY-ALIGNED LITERATURE: (a) Verdura et al. (Pharmaceuticals 2021, PMID 34208282) — CRISPR-based chemosensitivity screening in silibinin-treated NSCLC cells identified azaserine (HBP/GFAT1 inhibitor) as a selectively synergistic combination, defining the HBP as a targetable weakness in specific NSCLC subtypes — particularly KRAS/STK11 (LKB1) co-mutant tumors. This is the only direct azaserine-NSCLC primary study; it formally positions HBP/O-GlcNAc metabolic vulnerability as a CSC-metabolism target in lung cancer. (b) Xu W et al. (Exp Cell Res 2026, PMID 41999836) — GFPT1 (the azaserine-target enzyme) is overexpressed in lung adenocarcinoma (LUAD) and drives immune escape via MYC O-GlcNAcylation and PD-L1 upregulation; GFPT1 knoc...

SELECTIVE CANCER CELL TOXICITY is supported by multiple converging lines of evidence: (1) REDOX DIFFERENTIAL — TQ is a redox-active quinone that undergoes NADPH-cytochrome-P450-reductase-mediated one-electron reduction in cancer cells (which overexpress NQO1 and have elevated NADPH due to Warburg metabolism), generating semiquinone radicals and superoxide/hydrogen-peroxide that overwhelm the already-stressed cancer-cell antioxidant defences (low catalase, low GSH/GSSG ratio); normal cells with intact antioxidant capacity and lower basal ROS effectively detoxify TQ (PMID 31060003, Mahmoud & Abdelrazek). (2) NF-κB SELECTIVITY — NF-κB is constitutively active in NSCLC and most solid tumours but tightly regulated (inducible only) in normal cells; TQ's NF-κB suppression therefore disproportiona...

DIRECT NSCLC EVIDENCE (multiple primary studies): (a) Zhang et al. (Carcinogenesis 2023, PMID 37105709) — TQ inhibited lung cancer stem cell (LCSC) properties by triggering YAP phosphorylation/ubiquitination; YAP silencing enhanced TQ efficacy. Most direct LCSC evidence published. (b) Zheng et al. (Oncol Rep 2025, PMID 40970359) — HP-β-CD/TQ complex inhibited NSCLC progression through NF-κB-mediated ferroptosis. (c) Samarghandian et al. (J Cell Physiol 2019, PMID 30387147) — TQ induced p53/Bax/caspase-3/-9-mediated apoptosis in A549 NSCLC. (d) Alam et al. (J Cell Biochem 2022, PMID 34636440) — TQ + quercetin synergistically induced Bax/Bcl-2 cascade apoptosis in A549 NSCLC. (e) Alam et al. (Front Oncol 2022, PMID 35402265) — TQ positioned as EGFR-pathway/Bax-Bcl-2-targeting SMI in NSCLC al...

Selective cytotoxicity to cancer cells with relative sparing of normal cells is reported across multiple studies. Eupatorin shows dose-dependent cytotoxicity in MCF-7 and MDA-MB-231 breast cancer cells but is non-toxic to MCF-10a normal mammary epithelial cells (PMID 30728391). Sinensetin at 120 uM suppresses MCF7 and MDA-MB-231 breast cancer cell viability and promotes apoptosis with no significant toxicity to normal MCF-10A mammary cells (PMID 38410229). A standardised O. aristatus ethanolic extract inhibited A549 lung adenocarcinoma proliferation while sparing normal endothelial EA.hy926 cells (PMID 40258057). In a phase II RCT (Nuvastatic / C50SEW505OESA, 1000 mg TID x 9 weeks) in 110 solid-tumor patients receiving chemotherapy, the Orthosiphon rosmarinic-acid-rich extract significantl...

Direct NSCLC evidence for Kumis Kucing bioactives (sinensetin in particular) has expanded rapidly across 2024-2025: (1) Sinensetin reduced proliferation, migration, invasion, angiogenesis, and 'cancer stem characteristics of LUAD cells' via the miR-374c-5p / VEGF-A / VEGFR-2 / AKT axis in A549 xenografts (PMID 39030333) - the first explicit CSC-evidence in lung adenocarcinoma. (2) Sinensetin inactivated the AKT/beta-catenin axis in NSCLC cell lines A549 (IC50 81.46 uM) and H1299 (IC50 93.15 uM), reducing invasion and reprogramming the tumor immune microenvironment with increased CD8+ T-cell cytotoxicity (PMID 39434434) - beta-catenin is a master regulator of CSC self-renewal and immune evasion. (3) Sinensetin was identified as a selective MKK6 inhibitor (KD 66.27 uM) suppressing NSCLC prol...

summary: Selenium displays a uniquely context-dependent duality among trace elements — at physiological (nutritional, ~55 µg/day) concentrations it is an essential antioxidant via selenoprotein (GPx, TXNRD) expression and protects normal cells from oxidative DNA damage; at supranutritional (pharmacological, ≥200 µg/day; in vitro low-micromolar) concentrations it is a cancer-selective cytotoxic agent via redox cycling, methylselenol generation, GPx4 inhibition, and TrxR-mediated ROS amplification. The cancer-selectivity is mechanistically grounded in: (1) cancer cells overexpress Se-uptake machinery connected to multidrug resistance (PMID 19769465); (2) cancer cells overexpress thioredoxin reductase 1 (TrxR1), which reduces selenite to cytotoxic selenide and generates ROS selectively in tum...

direct_evidence: MULTIPLE DIRECT NSCLC IN VITRO/IN VIVO PRIMARY STUDIES: (a) Chen et al. (Cancer Chemother Pharmacol 2018, PMID 29546459) — Sodium selenite significantly inhibited LAD (lung adenocarcinoma) cell growth and induced apoptosis in a dose-dependent manner with MARGINAL EFFECTS on normal epithelial cell HBEC; SS dramatically REPRESSED SOX2 and its upstream regulator GLI1, and strongly decreased STEMNESS SPHERE FORMATION at 10 µM — direct lung cancer stem cell functional assay; forced SOX2 overexpression buffered anti-cancer effects — single most direct Se → lung CSC mechanism paper. (b) Chan et al. (Clin Epigenetics 2023, PMID 36864513) — Selenite is a DUAL APOPTOTIC AND FERROPTOTIC agent on EGFR-mutant H1975 (p.L858R + p.T790M) and KRAS-mutant H358 (p.G12C) lung adenocarcinoma c...

Bidirectional / context-dependent (a defining feature of CHL). In healthy / normal cells CHL is cytoprotective, antiapoptotic, and radioprotective: it activates Nrf2 + NF-κB, expands hematopoietic stem cells, rescues radiation-induced bone-marrow ablation, and rescues ifosfamide / cyclophosphamide / DPM / BaCl2-induced normal-tissue oxidative damage (PMID 25872101, 40488267, 40274623, 40005045, 40807405). In cancer cells CHL is antiproliferative, pro-apoptotic, and chemosensitising: it induces Bax/caspase-3/cytochrome c, suppresses Bcl-2, depletes GSH, releases Cu2+ → FDX1 → DLAT oligomerisation (cuproptosis), inhibits GSTP1, suppresses CYP1A1/1B1, intercalates DNA, and sensitises tumors to gemcitabine / docetaxel / ifosfamide / cyclophosphamide / photodynamic therapy (PMID 27458703, 40186...

Direct evidence base is small but mechanistically dense. (1) DIRECT NSCLC in vitro: Das et al. 2016 (PMID 27458703, Environ Toxicol Pharmacol) — PLGA nano-encapsulated CHL (NCHL) showed strong anti-cancer activity in A549 human non-small cell lung cancer cells via generation of ROS and modulation of Bax/Bcl-2/caspase-3/p53/cytochrome c (mitochondrial intrinsic apoptosis), plus DNA conformational change by intercalation; NCHL crossed the BBB in mice and reduced chromosomal aberrations and micronuclei in benzo[a]pyrene+sodium arsenite co-mutagen-treated mice at much reduced dose. (2) DIRECT CSC evidence: Bonuccelli et al. 2022 (PMID 36455875, Aging) screened natural products and FDA-approved drugs for inhibition of mammosphere-forming CSC propagation; chlorophyllin copper salt was identified...

Five operational principles distinguish melatonin's tumor-therapeutic from healthy-protective effects: (1) Redox context-dependence — in cancer cells with elevated basal ROS, suppressed catalase/GSH-pool, and high mito-membrane potential, melatonin acts as a pro-oxidant (elevates mito-ROS, MDA, NO, 8-oxo-dG, 4-HNE, PCC) and depletes GSH; in normal cells with intact antioxidant capacity it acts as a radical scavenger and Nrf2 inducer. (2) Receptor stoichiometry — both MT1 and MT2 are overexpressed in NSCLC vs non-malignant lung tissue, particularly in squamous histology; MT2 overexpression correlates with favorable prognosis in NSCLC, indicating that receptor-dense cancer cells are preferentially responsive. (3) Metabolic liability — melatonin restores SIRT3/PDH-driven OXPHOS in Warburg-shi...